# US 2015/0030699 A1 · Anti-tumor adjuvant therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0030699 A1
- Document ID: US20150030699A1
- Status: Published application
- Kind: A1
- Application number: 14/366,504
- Filed: 2012-12-27
- Published: 2015-01-29
- Earliest claimed: 2011-12-27
- Assignees: Universite Pierre Et Marie Curie (Paris 6); Institute Curie
- Applicants: Universite Pierre et Marie Curie (Paris 6); Institute Curie
- Inventors: Angelita Rebollo Garcia; Fariba Nemati; Didier Decaudin
- Web page: https://patentgrep.com/patent/US20150030699A1

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/664: Amides of phosphorus acids
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 33/243: Platinum; Compounds thereof
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/4747: {Apoptosis related proteins}
- C12N 9/6475: {Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to a chimeric peptide construct comprising a cell penetrating peptide linked to a pro-apoptotic peptide, for use in treating a tumor in combination with an anti-tumor agent, preferably a chemotherapeutic agent.

## Claims

### Claim 1

A chimeric peptide construct comprising a cell penetrating peptide linked to a pro-apoptotic peptide, for use in treating a tumor in combination with an anti-tumor agent, wherein the pro-apoptotic peptide comprises sequence is:
(SEQ ID NO: 3)
Y-X4a-ETLD-X4b-I-X5-EQWA-X6-S-X7
wherein
X4a is valine or isoleucine;
X4b is aspartic acid or glycine;
X5 is phenylalanine or leucine;
X6 is arginine or histidine;
X7 is vacant or is glutamate, or glutamate-aspartate, or glutamate-aspartate-leucine; or
a proteolysis-resistant peptide deriving from said pro-apoptotic peptide by one or more chemical modifications, or a substantially homologous peptide, preferably deriving from SEQ ID NO: 3 by one or more conservative substitutions,

### Claim 2 (depends on 1)

The chimeric peptide construct for use in treating a tumor in combination with an anti-tumor agent according to claim 1, wherein
X4a is valine;
X4b is aspartic acid;
X5 is phenylalanine; and
X6 is histidine.

### Claim 3 (depends on 1)

The chimeric peptide construct for use in treating a tumor in combination with an anti-tumor agent according to claim 1, wherein said cell-penetrating peptide is:
(SEQ ID NO: 4)
a) X1-KKKIK-Ψ-EI-X2-X3
wherein X1 is vacant, is a lysine residue, or valine-lysine;
X2 is vacant, is a lysine residue, or lysine-isoleucine;
X3 is vacant or is an amino acid sequence of one to 4 amino acids; and
ψ is any amino-acid;
or a proteolysis-resistant peptide deriving from SEQ ID NO: 4 by one or more chemical modifications, or a substantially homologous peptide deriving from SEQ ID NO:4 by one or more conservative substitutions,
(SEQ ID NO: 5)
b) (RQKRLI)3,
(SEQ ID NO: 6)
(RHSRIG)3,
(SEQ ID NO: 7)
RHSRIGIIQQRRTRNG,
(SEQ ID NO: 8)
RHSRIGVTRQRRARNG,
(SEQ ID NO: 9)
RRRRRRRSRGRRRTY,
or
c) Tat peptide, polyarginines peptide, HA2-R9 peptide, Penetratin peptide, Transportan peptide, Vectocell peptide, maurocalcine peptide, decalysine peptide, HIV-Tat derived PTD4 peptide, Hepatitis B virus Translocation Motif (PTM) peptide, mPrP1-28 peptide, POD, pVEC, EB1, Rath, CADY, Histatin 5, Antp peptide, or Cyt86-101 peptide.

### Claim 4 (depends on 3)

The chimeric peptide construct for use in treating a tumor in combination with an anti-tumor agent according to claim 3, wherein said cell-penetrating peptide is
(SEQ ID NO: 4)
X1-KKKIK-Ψ-EI-X2-X3
wherein ψ is arginine, alanine, lysine, or asparagine.

### Claim 5 (depends on 3)

The chimeric peptide construct for use in treating a tumor in combination with an anti-tumor agent according to claim 3, wherein said cell-penetrating peptide is
(SEQ ID NO: 4)
X1-KKKIK-Ψ-EI-X2-X3
wherein ψ is arginine, alanine, lysine, or asparagine;
X1 is valine-lysine;
X2 is lysine-isoleucine; and
X3 is vacant.

### Claim 6 (depends on 5)

The chimeric peptide construct for use in treating a tumor in combination with an anti-tumor agent according to claim 5, wherein said cell-penetrating peptide is VKKKKIKREIKI (SEQ ID NO:39), VKKKKIKAEIKI (SEQ ID NO:40), VKKKKIKKEIKI (SEQ ID NO:41) or VKKKKIKNEIKI (SEQ ID NO:42).

### Claim 7 (depends on 6)

The chimeric peptide construct for use in treating a tumor in combination with an anti-tumor agent according to claim 6, which is selected from the group consisting of:
(SEQ ID NO: 29)
VKKKKIKREIKI-YVETLDDIFEQWAHSEDL
(SEQ ID NO: 30)
VKKKKIKREIKI-YIETLDDILEQWARSEDL
(SEQ ID NO: 31)
VKKKKIKAEIKI-YVETLDDIFEQWAHSEDL
(SEQ ID NO: 32)
VKKKKIKAEIKI-YIETLDDILEQWARSEDL
(SEQ ID NO: 33)
VKKKKIKKEIKI-YVETLDDIFEQWAHSEDL
(SEQ ID NO: 34)
VKKKKIKKEIKI-YIETLDDILEQWARSEDL
(SEQ ID NO: 35)
VKKKKIKNEIKI-YVETLDDIFEQWAHSEDL
and
(SEQ ID NO: 36)
VKKKKIKNEIKI-YIETLDDILEQWARSEDL

### Claim 8 (depends on 1)

A method of treating a tumor, comprising administering to a subject in need thereof the chimeric peptide construct according to claim 1 and an anti-tumor agent, wherein the tumor is a cancer selected from the group consisting of acute myelogenous leukaemia, chronic lymphocytic leukaemia, multiple myeloma, Hodgkin's disease, non-Hodgkin's lymphoma, B cell, cutaneous T cell lymphoma, uveal melanoma, melanoma and brain, lung, breast, ovarian, head and neck, bladder, gastric, pancreatic, head, neck, renal, prostate, colorectal, oesophageal, and thyroid cancer.

### Claim 9 (depends on 8)

The method of claim 8, wherein the chimeric peptide construct and the anti-tumor agent are sequentially administered.

### Claim 10 (depends on 8)

The method of claim 8, wherein the anti-tumor agent is a chemotherapeutic agent.

### Claim 11 (depends on 10)

The method of claim 10, wherein a chemotherapeutic agent is doxorubicin and/or cyclophosphamide.

### Claim 12 (depends on 10)

The method of claim 10, wherein the anti-tumor agent is a chemotherapeutic agent that is docetaxel, 5-FU or cisplatin.

### Claim 13 (depends on 11)

The method of claim 11, wherein the tumor is a breast cancer.

### Claim 14 (depends on 10)

The method of claim 10, wherein the peptide construct is administered after a period of about 5 to about 30 days after the chemotherapeutic agent is administered.

### Claim 15 (depends on 1)

A method of preventing relapse of a tumor, comprising administering to a subject in need thereof the chimeric peptide construct according to claim 1 and an anti-tumor agent.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A macromolecule for use in treating a tumor in combination with an anti-tumor agent, the macromolecule being a nucleic acid encoding the chimeric peptide construct as defined in of claim 1 or a vector comprising said nucleic acid.

### Claim 18 (depends on 17)

The macromolecule according to claim 17, wherein the macromolecule is an adenovirus or a lentivirus vector.

### Claim 19 (depends on 2)

The chimeric peptide construct for use in treating a tumor in combination with an anti-tumor agent according to claim 2, wherein said cell-penetrating peptide is selected from:
(SEQ ID NO: 4)
a) X1-KKKIK-Ψ-EI-X2-X3
wherein X1 is vacant, is a lysine residue, or valine-lysine;
X2 is vacant, is a lysine residue, or lysine-isoleucine;
X3 is vacant or is an amino acid sequence of one to 4 amino acids; and
ψ is any amino-acid;
or a proteolysis-resistant peptide deriving from SEQ ID NO: 4 by one or more chemical modifications, or a substantially homologous peptide deriving from SEQ ID NO:4 by one or more conservative substitutions,
(SEQ ID NO: 5)
b) (RQKRLI)3,
(SEQ ID NO: 6)
(RHSRIG)3,
(SEQ ID NO: 7)
RHSRIGIIQQRRTRNG,
(SEQ ID NO: 8)
RHSRIGVTRQRRARNG,
(SEQ ID NO: 9)
RRRRRRRSRGRRRTY,
or
c) Tat peptide, polyarginines peptide, HA2-R9 peptide, Penetratin peptide, Transportan peptide, Vectocell peptide, maurocalcine peptide, decalysine peptide, HIV-Tat derived PTD4 peptide, Hepatitis B virus Translocation Motif (PTM) peptide, mPrP1-28 peptide, POD, pVEC, EB1, Rath, CADY, Histatin 5, Antp peptide, or Cyt86-101 peptide.

### Claim 20 (depends on 4)

The chimeric peptide construct for use in treating a tumor in combination with an anti-tumor agent according to claim 4, wherein said cell-penetrating peptide is
(SEQ ID NO: 4)
X1-KKKIK-Ψ-EI-X2-X3
wherein ψ is arginine, alanine, lysine, or asparagine;
X1 is valine-lysine;
X2 is lysine-isoleucine; and
X3 is vacant.

### Claim 21 (depends on 19)

The chimeric peptide construct for use in treating a tumor in combination with an anti-tumor agent according to claim 19, wherein said cell-penetrating peptide is
(SEQ ID NO: 4)
X1-KKKIK-Ψ-EI-X2-X3
wherein ψ is arginine, alanine, lysine, or asparagine;
X1 is valine-lysine;
X2 is lysine-isoleucine; and
X3 is vacant.
